Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Talquetamab Wins Approval in Europe for Relapsed/Refractory Myeloma

August 22nd 2023

The European Commission has granted conditional marketing authorization to talquetamab-tgvs monotherapy for the treatment of patients with relapsed/refractory multiple myeloma who have received at least 3 prior therapies and have demonstrated disease progression on the last therapy.

Dr Schinke on the Safety Profile of Talquetamab in Relapsed/Refractory Myeloma

August 21st 2023

Carolina D. Schinke, MD, discusses the safety profile of talquetamab-tgvs in the phase 1/2 MonumenTAL-1 trial of patients with relapsed/refractory multiple myeloma.

Educating on Multiple Myeloma: Patient and Physician Resources

August 21st 2023

Shared insight from key opinion leaders on educational resources made available to physicians and patients, respectively, regarding multiple myeloma management.

Multiple Myeloma: Challenges in Diagnosis and Role of Multidisciplinary Care

August 21st 2023

Opening its discussion on key unmet needs in multiple myeloma management, a panel of experts discuss key challenges faced when diagnosing patients with multiple myeloma and review the impact of having a multidisciplinary care team.

Talquetamab Helps Usher in Era of Bispecific Antibodies in Relapsed/Refractory Myeloma

August 18th 2023

Ajai Chari, MD, discusses how the FDA approval of talquetamab addresses several unmet needs in relapsed/refractory multiple myeloma and expands on the agent’s efficacy data and safety profile observed in MonumenTAL-1.

European Commission Approves Reduced Dosing of Teclistamab in Relapsed/Refractory Myeloma

August 18th 2023

The European Commission has approved a Type II variation application for teclistamab, providing the option for a reduced dosing frequency of 1.5 mg/kg every 2 weeks in patients with relapsed/refractory multiple myeloma who have achieved a complete response or better for a minimum of 6 months.

Dr Schinke on the Rationale for the MonumenTAL-1 Trial in Multiple Myeloma

August 16th 2023

Carolina D. Schinke, MD, discusses the rationale for conducting the phase 1/2 MonumenTAL-1 trial in patients with multiple myeloma.

Dr Dholaria on Ongoing Investigations of Talquetamab and Daratumumab in R/R Multiple Myeloma

August 16th 2023

Bhagirathbhai Dholaria, MBBS, discusses next steps for investigating subcutaneous talquetamab and daratumumab in relapsed/refractory multiple myeloma based on data from the phase 1 TRIMM-2 trial.

Dr Patel on Maintaining Quality of Life While Treating Patients With Multiple Myeloma

August 15th 2023

Krina K. Patel, MD, MSc, discusses maintaining quality of life while treating patients with multiple myeloma, as well as highlights from the phase 3 KarMMa-3 trial.

FDA Lifts Clinical Hold on BCMA-Directed Modified CAR T-Cell Therapy in Multiple Myeloma

August 15th 2023

The FDA has lifted the partial clinical hold placed on the clinical program evaluating the investigational new drug, CART-ddBCMA, in the treatment of patients with relapsed/refractory multiple myeloma.

FDA Approves Elranatamab for Relapsed or Refractory Multiple Myeloma

August 14th 2023

The FDA has granted accelerated approval to elranatamab-bcmm (Elrexfio) for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously received at least 4 lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Teclistamab Plus Nirogacestat Elicits Durable Responses in Relapsed/Refractory Myeloma

August 11th 2023

The combination of teclistamab and nirogacestat produced high and deep responses in patients with relapsed/refractory multiple myeloma.

Linvoseltamab Produces Durable Responses in Relapsed/Refractory Multiple Myeloma

August 10th 2023

Hans Lee, MD, discusses unmet needs in patients with relapsed/refractory multiple myeloma, highlights key efficacy and safety findings from the LINKER-MM1 trial, and how these data may inform the future of the multiple myeloma treatment paradigm.

FDA Approves Talquetamab for Relapsed/Refractory Multiple Myeloma

August 10th 2023

The FDA has granted accelerated approval to talquetamab-tgvs for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.

Dr Patel on the Background of the KarMMa-3 Trial in Relapsed/Refractory Multiple Myeloma

August 8th 2023

Krina K. Patel, MD, MSc, discusses the background of the phase 3 KarMMa-3 trial, which investigated idecabtagene vicleucel in patients with high-risk, relapsed/refractory multiple myeloma.

Multiple Myeloma: Unmet Needs and Future Directions in Care

August 8th 2023

After discussing earlier-line use of CAR T-cell therapy in patients with multiple myeloma, the panel considers key takeaways and future evolutions in the treatment landscape.

CAR T-Cell Therapy in Multiple Myeloma: Updates from ASCO 2023 and Beyond

August 8th 2023

Before closing out their discussion on novel therapies in multiply relapsed multiple myeloma, panelists identify the evolving role of CAR T-cell therapy.

Dr Mohty on the Promise of Elranatamab in Relapsed/Refractory Multiple Myeloma

August 3rd 2023

Mohamad Mohty, MD, PhD, discusses the promise of the phase 2 MagnetisMM-3 trial in patients with relapsed/refractory multiple myeloma, which is investigating elranatamab monotherapy in this patient population.

Talquetamab Produces Durable Responses in Relapsed/Refractory Multiple Myeloma

August 2nd 2023

Carolina D. Schinke, MD, discusses key efficacy findings from the MonumenTAL-1 trial, adverse effects to be aware of with talquetamab, and what the findings from this trial reveal about the potential future for talquetamab and other bispecific antibodies in patients with multiple myeloma.

Dr Costa on the Background of the MASTER Trial in Newly Diagnosed Multiple Myeloma

August 1st 2023

Luciano J. Costa, MD, PhD, discusses the background of the phase 2 MASTER trial in newly diagnosed multiple myeloma.